Novartis: Oddo still on hold

(CercleFinance.com) - Oddo maintains its "neutral" rating on Novartis shares, with an unchanged price target of 90 Swiss francs.


The company announced positive results from a Phase III study evaluating Kisqali as an adjuvant treatment in HR+/HER2- early breast cancer.

An adjuvant approval would enable Novartis to significantly expand its market, as over 80% of patients with HR+/HER2- breast cancer are diagnosed at an early stage, the analyst said.

Oddo believes that the consensus could raise its peak sales forecast to $4-5bn (vs. $3bn).


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.